Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY - Get Free Report) have been given an average rating of "Buy" by the eight research firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company.
Several brokerages recently issued reports on RBGLY. Barclays cut Reckitt Benckiser Group from an "overweight" rating to an "equal weight" rating in a research note on Tuesday, February 4th. Royal Bank of Canada reissued an "outperform" rating on shares of Reckitt Benckiser Group in a report on Friday, March 7th.
Read Our Latest Research Report on RBGLY
Reckitt Benckiser Group Stock Performance
OTCMKTS RBGLY traded down $0.01 during trading on Tuesday, reaching $13.03. The company's stock had a trading volume of 291,001 shares, compared to its average volume of 378,091. The firm has a 50 day moving average price of $13.16 and a 200 day moving average price of $12.74. Reckitt Benckiser Group has a 12 month low of $10.43 and a 12 month high of $14.10. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.47 and a current ratio of 0.69.
Reckitt Benckiser Group Increases Dividend
The company also recently disclosed a dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 11th will be issued a dividend of $0.2909 per share. This is an increase from Reckitt Benckiser Group's previous dividend of $0.19. The ex-dividend date is Friday, April 11th.
About Reckitt Benckiser Group
(
Get Free ReportReckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
